Yılmaz, A. Et Al. 2021. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. FUTURE ONCOLOGY , vol.17, no.33 , 4545-4559.

Yılmaz, A., Şimşek, M., Hannarici, Z., Buyukbayram, M. E., Bilici, M., & Tekin, S. B., (2021). The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib. FUTURE ONCOLOGY , vol.17, no.33, 4545-4559.

Yılmaz, Ali Et Al. "The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib," FUTURE ONCOLOGY , vol.17, no.33, 4545-4559, 2021

Yılmaz, Ali Et Al. "The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib." FUTURE ONCOLOGY , vol.17, no.33, pp.4545-4559, 2021

Yılmaz, A. Et Al. (2021) . "The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib." FUTURE ONCOLOGY , vol.17, no.33, pp.4545-4559.

@article{article, author={Ali YILMAZ Et Al. }, title={The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib}, journal={FUTURE ONCOLOGY}, year=2021, pages={4545-4559} }